Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 48

1.

Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology.

Tanghetti EA, Stein Gold L, Del Rosso JQ, Lin T, Angel A, Pillai R.

J Dermatolog Treat. 2019 Sep 26:1-8. doi: 10.1080/09546634.2019.1668907. [Epub ahead of print]

PMID:
31522563
2.

Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study.

Lebwohl MG, Blauvelt A, Menter A, Papp KA, Guenthner S, Pillai R, Israel RJ, Jacobson A.

Am J Clin Dermatol. 2019 Dec;20(6):863-871. doi: 10.1007/s40257-019-00466-2.

4.
5.

Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of safety and tolerability in subgroups.

Harper JC, Roberts WE, Zeichner JA, Guenin E, Bhatt V, Pillai R.

J Dermatolog Treat. 2020 Mar;31(2):160-167. doi: 10.1080/09546634.2019.1587884. Epub 2019 Apr 2.

PMID:
30935257
6.

Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis

Blauvelt A, Green LJ, Lebwohl MG, Yamauchi PS, Lin T, Martin G, Pillai R.

J Drugs Dermatol. 2019 Mar 1;18(3):297-299.

PMID:
30909352
7.

Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis

Kircik LH, Papp KA, Stein Gold L, Harris S, Pharm TL, Pillai R.

J Drugs Dermatol. 2019 Mar 1;18(3):279-284..

PMID:
30909333
8.

Safety and efficacy of halobetasol propionate lotion 0.01% in the treatment of moderate to severe plaque psoriasis: a pooled analysis of 2 phase 3 studies.

Sugarman JL, Weiss JS, Tanghetti EA, Soung J, Yamauchi PS, Lin T, Harris S, Martin G, Pillai R.

Cutis. 2019 Feb;103(2):111-116.

PMID:
30893392
9.

Halobetasol 0.01%/Tazarotene 0.045% Fixed-combination Lotion in the Treatment of Plaque Psoriasis: Sensitization and Irritation Potential.

Del Rosso JQ, Kircik L, Lin T, Pillai R.

J Clin Aesthet Dermatol. 2019 Jan;12(1):11-15. Epub 2019 Jan 1.

10.
11.

Halobetasol and Tazarotene: Further Defining the Role of a Unique Fixed Combination Topical Lotion in Moderate-to-Severe Plaque Psoriasis

Stein Gold L, Bagel J, Lebwohl M, Lin T, Martin G, Pillai R.

J Drugs Dermatol. 2018 Dec 1;17(12):1290-1296.

PMID:
30586261
12.

Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Assessment of Efficacy and Safety in Patients Aged 9 Years and Older.

Tyring SK, Kircik LH, Pariser DM, Guenin E, Bhatt V, Pillai R.

J Drugs Dermatol. 2018 Oct 1;17(10):1084-1091.

PMID:
30365589
13.

Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials.

Green LJ, Kerdel FA, Cook-Bolden FE, Bagel J, Lin T, Martin G, Pillai R, Israel R, Ramakrishna T.

J Drugs Dermatol. 2018 Oct 1;17(10):1062-1069.

PMID:
30365586
14.

Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis.

Lebwohl MG, Sugarman JL, Gold LS, Pariser DM, Lin T, Pillai R, Martin G, Harris S, Israel R.

J Am Acad Dermatol. 2019 Jan;80(1):282-285. doi: 10.1016/j.jaad.2018.09.002. Epub 2018 Sep 15. No abstract available.

15.
16.

Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination.

Stein Gold L, Kircik LH, Pariser D, Sugarman JL, Lin T, Kang R, Pillai R.

J Drugs Dermatol. 2018 Aug 1;17(8):863-868.

PMID:
30124725
17.

Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies.

Sugarman JL, Weiss J, Tanghetti EA, Bagel J, Yamauchi PS, Stein Gold L, Lin T, Martin G, Pillai R, Israel R.

J Drugs Dermatol. 2018 Aug 1;17(8):855-861.

PMID:
30124724
18.

Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.

Pariser DM, Green LJ, Stein Gold L, Sugarman JL, Lin T, Pillai R.

J Drugs Dermatol. 2018 Jul 1;17(7):723-726.

PMID:
30005093
19.

Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials.

Gold LS, Lebwohl MG, Sugarman JL, Pariser DM, Lin T, Martin G, Pillai R, Israel R, Ramakrishna T.

J Am Acad Dermatol. 2018 Aug;79(2):287-293. doi: 10.1016/j.jaad.2018.03.040. Epub 2018 Apr 1.

20.

Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials.

Lebwohl MG, Papp KA, Marangell LB, Koo J, Blauvelt A, Gooderham M, Wu JJ, Rastogi S, Harris S, Pillai R, Israel RJ.

J Am Acad Dermatol. 2018 Jan;78(1):81-89.e5. doi: 10.1016/j.jaad.2017.08.024. Epub 2017 Oct 3. Review.

PMID:
28985956

Supplemental Content

Loading ...
Support Center